Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform - PubMed
6 hours ago
- #FDA Guidance
- #Genetic Disorders
- #Prime Editing
- FDA's 2026 draft guidance introduces a plausible mechanism framework for individualized genetic therapies.
- Proof-of-concept studies demonstrate a customizable prime editing platform for 7 urea cycle disorders and other liver disorders.
- Discussed with FDA an 'umbrella-of-umbrellas' clinical trial design for multiple UCDs using the platform.
- Aims to facilitate faster FDA approvals for ultra-rare diseases under the new framework.
- Highlights conflict of interests with authors involved in biotech firms and research funding.